title: Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus.
abstract: KCNJ11 polymorphisms have been linked to the risk of developing type 2 diabetes. Our aim was to define the contribution of KCNJ11 to new-onset diabetes after transplantation (NODAT) among patients treated with Tacrolimus (Tac). A total of 115 NODAT and 205 non-NODAT were genotyped for rs5219 (p.E23K). AA+AG genotypes were significantly associated with NODAT-risk (p=0.004; OR=2.10). The reported effect of this KCNJ11 polymorphism on insulin release by beta cells could explain this association.
authors.affiliation: Genética Molecular, Hospital Universitario Central de Asturias, Oviedo, Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Tavira
authors.forename: Eliecer
authors.initials: E
authors.lastname: Coto
authors.forename: Armando
authors.initials: A
authors.lastname: Torres
authors.forename: Carmen
authors.initials: C
authors.lastname: Díaz-Corte
authors.forename: Beatriz
authors.initials: B
authors.lastname: Díaz-Molina
authors.forename: Francisco
authors.initials: F
authors.lastname: Ortega
authors.forename: Manuel
authors.initials: M
authors.lastname: Arias
authors.forename: Juan M
authors.initials: JM
authors.lastname: Díaz
authors.forename: Rafael
authors.initials: R
authors.lastname: Selgas
authors.forename: Carlos
authors.initials: C
authors.lastname: López-Larrea
authors.forename: Marta
authors.initials: M
authors.lastname: Ruiz-Ortega
authors.forename: Alberto
authors.initials: A
authors.lastname: Ortiz
authors.forename: Elena
authors.initials: E
authors.lastname: González
authors.forename: Josep M
authors.initials: JM
authors.lastname: Campistol
authors.forename: Victoria
authors.initials: V
authors.lastname: Alvarez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D065095:Calcineurin Inhibitors; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000235:genetics*; D005260:Female; D005838:Genotype; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics*; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult; D000099161:Kcnj11 Channel
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D007328:Insulin; D024661:Potassium Channels, Inwardly Rectifying; D016559:Tacrolimus; D000099161:Kcnj11 Channel